PRESS RELEASE published on 01/23/2025 at 18:45, 10 months 13 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie sa situation financière 2024 et donne des mises à jour sur ses activités, y compris le financement et la progression réglementaire de LUMEVOQ. La trésorerie s'élève à 2,5M€ à fin 2024 Financement Trésorerie Situation Financière GenSight Biologics LUMEVOQ
PRESS RELEASE published on 01/23/2025 at 18:45, 10 months 13 days ago Inside Information / News release on accounts, results GenSight Biologics reports end-of-year cash position and provides business update, including successful capital increases and ongoing review of LUMEVOQ dossier Business Update Cash Position GenSight Biologics Capital Increases LUMEVOQ Dossier
BRIEF published on 01/15/2025 at 07:35, 10 months 21 days ago GenSight Biologics publie les résultats à long terme de LUMEVOQ® Thérapie Génique GenSight Biologics LUMEVOQ® Acuité Visuelle Neuropathie Optique Héréditaire De Leber
BRIEF published on 01/15/2025 at 07:35, 10 months 21 days ago GenSight Biologics Reports Long-Term Results for LUMEVOQ® Gene Therapy GenSight Biologics LUMEVOQ® Visual Acuity Leber's Hereditary Optic Neuropathy
PRESS RELEASE published on 01/15/2025 at 07:30, 10 months 21 days ago Informations privilégiées / Autres communiqués GenSight Biologics annonce les résultats cliniques à 5 ans de la thérapie génique LUMEVOQ chez les patients atteints de NOHL, démontrant une amélioration bilatérale de l'acuité visuelle et un profil de sécurité favorable Thérapie Génique GenSight Biologics NOHL LUMEVOQ Résultats Cliniques
PRESS RELEASE published on 01/15/2025 at 07:30, 10 months 21 days ago Inside Information / Other news releases GenSight Biologics announces the publication of 5-year outcomes for patients treated with LUMEVOQ® gene therapy, showing sustained bilateral improvement in visual acuity and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity Safety Profile
BRIEF published on 01/13/2025 at 11:31, 10 months 23 days ago Heights Capital Management dépasse 5% du capital de GenSight Biologics Augmentation De Capital GenSight Biologics Actions Et Droits De Vote Heights Capital Management Participation Capital
BRIEF published on 01/13/2025 at 11:31, 10 months 23 days ago Heights Capital Management exceeds 5% stake in GenSight Biologics Capital Increase Shares And Voting Rights GenSight Biologics Heights Capital Management Capital Participation
PRESS RELEASE published on 01/13/2025 at 11:26, 10 months 23 days ago Franchissement de seuils Déclaration de franchissement de seuils par Heights Capital Management, Inc. pour Gensight Biologics S.A. avec détention de 7 574 746 actions et 9,62% des droits de vote Déclaration Actions Franchissement De Seuils Gensight Biologics S.A. Heights Capital Management Inc.
BRIEF published on 12/24/2024 at 20:51, 11 months 11 days ago GenSight Biologics Secures €1.5 Million Financing from Existing Investors Investors Warrants Financing Gene Therapy GenSight Biologics
Published on 12/05/2025 at 19:20, 27 minutes ago The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 1 hour 2 minutes ago Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:20, 1 hour 27 minutes ago NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 1 hour 47 minutes ago SMX: A New Supply Chain Reality in the World's Four Largest Markets
Published on 12/05/2025 at 17:15, 2 hours 32 minutes ago TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 18:58, 49 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 1 hour 31 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:46, 2 hours ago Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:18, 2 hours 29 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 2 hours 29 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 4 hours 36 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 4 hours 36 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 5 hours 48 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
